Explorar vídeo

Integrating pomalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (RRMM) involves using them as a core regimen, often combined with other agents like bortezomib or monoclonal antibodies for enhanced efficacy.

View comprehensive coverage of Breast Cancer from ESMO 2022

PEACE-1 clinical trial demonstrated that combining ADT and docetaxel with abiraterone acetate plus prednisone (AAP) improves both overall survival (OS) and radiographic progression-free-survival (rPFS) in men with de novo mCSPC.

ASH 2022 - Update on Myelodysplastic Syndromes

Wherever possible all patients with prostate cancer should undergo both germinal and somatic BRCA mutation testing as they represent predictive biomarkers of greater sensitivity to treatment with PARP inhibitors.

There are no randomized clinical trials addressing the continued use of Trastuzumab for Her2 positive MBC patients in prolonged remission and has become important and relevant clinical question.

EHA Updates AML : QuANTUM phase 3 study showed significant overall survival in adults having FLT3-ITD+ acute myeloid leukaemia with  addition of quizartinib to standard induction and consolidation therapy alone.

Bone marrow examination-based diagnosis of MDS with either biopsy or aspirate remains standard of care but is associated with pain, bleeding, difficulty to use the same in elderly patients and hIgh interobserver variability.

Integrating molecular prognostic systems into MDS clinical practice enhances risk stratification by combining genetic data with traditional scoring systems.

I-SPY2 clinical trial laid the foundation for Immunotherapy in Early Breast Cancer with Pembrolizumab added to Neoadjuvant Chemotherapy.